Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi

Experimental Parasitology

Volumn 130, Issue 3, 2012, Pages 195-199

  Reimão, Juliana Q ^a   Colombo, Fábio A ^a   Pereira Chioccola, Vera L ^a   Tempone, André G ^a  

^a INSTITUTO ADOLFO LUTZ   (Brazil)

Author keywords

Buparvaquone; Leishmania (L.) infantum chagasi; Leishmaniasis; Liposomes; Therapy

Indexed keywords

BUPARVAQUONE; LIPOSOME; MEGLUMINE ANTIMONATE; PHOSPHATIDYLSERINE; RNA;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG STRUCTURE; EXPERIMENTAL MODEL; HAMSTER; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA CHAGASI; LEISHMANIA INFANTUM; LEISHMANIASIS; LIVER; MAMMAL CELL; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROMASTIGOTE; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; SPECIES DIFFERENCE; SPLEEN; STRUCTURE ANALYSIS; TREATMENT FAILURE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; ANTIPROTOZOAL AGENTS; CELL LINE; CELLS, CULTURED; CRICETINAE; DISEASE MODELS, ANIMAL; HUMANS; INHIBITORY CONCENTRATION 50; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; LIPOSOMES; MACACA MULATTA; MACROPHAGES, PERITONEAL; MALE; MESOCRICETUS; MICE; MICE, INBRED BALB C; NAPHTHOQUINONES; PHOSPHATIDYLSERINES;

CRICETINAE; LEISHMANIA INFANTUM; MAMMALIA;

EID: 84857458324     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2012.01.010     Document Type: Article

References (24)

1. Bern C., Adler-Moore J., Berenguer J., Boelaert M., den Boer M., Davidson R.N. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2006, 43:917-924.
2. Colombo F.A., Odorizzi R.M., Laurenti M.D., Galati E.A., Canavez F., Pereira-Chioccola V.L. Detection of Leishmania (Leishmania) infantum RNA in fleas and ticks collected from naturally infected dogs. Parasitology Research 2011, 109:267-274.
3. Croft S.L., Hogg J., Gutteridge W.E., Hudson A.T., Randall A.W. The activity of hydroxynaphthoquinones against Leishmania donovani. The Journal of Antimicrobial Chemotherapy 1992, 30:827-832.
4. den Boer M.L., Alvar J., Davidson R.N., Ritmeijer K., Balasegaram M. Developments in the treatment of visceral leishmaniasis. Expert Opinion on Emerging Drugs 2009, 14:395-410.
5. Frézard F., Demicheli C. New delivery strategies for the old pentavalent antimonial drugs. Expert Opinion on Drug Delivery 2010, 2010(7):1343-1358.
6. Garnier T., Mäntylä A., Järvinen T., Lawrence J., Brown M., Croft S. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. The Journal of Antimicrobial Chemotherapy 2007, 60:802-810.
7. Gokhale N.H., Padhye S.B., Croft S.L., Kendrick H.D., Davies W., Anson C.E. Transition metal complexes of buparvaquone as potent new antimalarial agents. 1. Synthesis, X-ray crystal-structures, electrochemistry and antimalarial activity against Plasmodium falciparum. Journal of Inorganic Biochemistry 2003, 95:249-258.
8. Grimaldi G., Tesh R.B. Leishmaniases of the New World: current concepts and implications for future research. Clinical Microbiology Reviews 1993, 6:230-250.
9. Maltezou H.C. Visceral leishmaniasis: advances in treatment. Recent Patents on Anti-infective Drug Discovery 2008, 3:192-198.
10. Manna L., Gravino A.E., Picillo E., Decaro N., Buonavoglia C. Leishmania DNA quantification by real-time PCR in naturally infected dogs treated with miltefosine. Annals of the New York Academy of Sciences 2008, 1149:358-360.
11. Mäntylä A., Mäntylä A., Garnier T., Rautio J., Nevalainen T., Vepsälainen J. Synthesis, in vitro evaluation and antileishmanial activity of water-soluble prodrugs of buparvaquone. Journal of Medicinal Chemistry 2004, 47:188-195.
12. Müller R.H., Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. International Journal of Pharmaceutics 2002, 237:151-161.
13. Murray H.W. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrobial Agents and Chemotherapy 2001, 45:2185-2297.
14. New R.R.C. Liposomes: A Practical Approach 1992, University Press, Oxford.
15. Reimão J.Q., Colombo F.A., Pereira-Chioccola V.L., Tempone A.G. In vitro and experimental therapeutic studies of the calcium channel blocker bepridil: Detection of viable Leishmania (L.) chagasi by real-time PCR. Experimental Parasitology 2011, 128:111-115.
16. Reimão J.Q., Taniwaki N.N., Tempone A.G. Furazolidone is a selective in vitro candidate against Leishmania (L.) chagasi: an ultrastructural study. Parasitolology Research 2010, 106:1465-1469.
17. Sudarshan M., Weirather J.L., Wilson M.E., Sundar S. Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis. The Journal of Antimicrobial Chemotherapy 2011, 66:1751-1755.
18. Sundar S., Sinha P.K., Verma D.K., Kumar N., Alam S., Pandey K. Ambisome plus miltefosine for Indian patients with kala-azar. Transactions of the Royal Society of Tropical Medicine and Hygiene 2011, 105:115-117.
19. Tada H., Shiho O., Kuroshima K., Koyama M., Tsukamoto K. An improved colorimetric assay for interleukin 2. Journal of Immunological Methods 1986, 93:157-165.
20. Tempone A.G., Mortara R.A., de Andrade H.F., Reimão J.Q. Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis. International Journal of Antimicrobial Agents 2010, 36:159-163.
21. Tempone A.G., Perez D., Rath S., Vilarinho A.L., Mortara R.A., de Andrade H.F. Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine. The Journal of Antimicrobial Chemotherapy 2004, 54:60-68.
22. Torres D.C., Adaui V., Ribeiro-Alves M., Romero G.A., Arévalo J., Cupolillo E., Dujardin J.C. Targeted gene expression profiling in Leishmania braziliensis and Leishmania guyanensis parasites isolated from Brazilian patients with different antimonial treatment outcomes. Infection, Genetics and Evolution 2010, 10:727-733.
23. Venkatesh G., Majid M.I., Ramanathan S., Mansor S.M., Nair N.K., Croft S.L. Optimization and validation of RP-HPLC-UV method with solid-phase extraction for determination of buparvaquone in human and rabbit plasma: application to pharmacokinetic study. Biomedical Chromatography 2008, 22:535-541.
24. Vexenat J.A., Croft S.L., Furtado-Campos J.H., Miles M.A. Failure of buparvaquone (Butalex) in the treatment of canine visceral leishmaniosis. Veterinary Parasitology 1998, 77:71-73.